Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab

The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Weifeng, Tummala, Raj, Almquist, Joachim, Hwang, Michael, White, Wendy I., Boulton, David W., MacDonald, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182164/
https://www.ncbi.nlm.nih.gov/pubmed/37148484
http://dx.doi.org/10.1007/s40262-023-01238-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182164/
https://www.ncbi.nlm.nih.gov/pubmed/37148484
http://dx.doi.org/10.1007/s40262-023-01238-2

Ejemplares similares